Skip to main content

Table 3 Univariate analysis for PFS

From: EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition

  Correlative cohort (n = 66) Anti-EGFR treated (n = 39)
  Median p Median p
Smoking history   0.246   0.238
  Never smokers 5.0   3.2  
  Former smokers 5.0   5.6  
  Current smokers 7.0   10.0  
Stage   0.130   0.423
  IIIB 7.6   11.4  
  IV 5.0   4.8  
Age   0.233   0.894
<70 years 5.5   7.2  
70years 6.5   5.0  
EGFR mutation*   0.373   0.052
  Exon 19 mutation 4.4   12.7  
  Exon 20 mutation 8.0   NA  
  Exon 21 mutation 3.2   1.4  
  1. Abbreviations: PFS progression-free survival, NA not applicable. *Analysis is restricted to EGFR mutant patients only.